Role of Neoadjuvant Chemotherapy in Stage 1, 2a Breast Cancer in Female Patients Breast Cup (A-C)

Abstract

Abstract Background breast cancer is considered the most common cancer diagnosed in women worldwide with an incidence of 1.7 million new cancer cases in 2012. It is the fifth most common cause for cancer related mortality worldwide with a trend for increased mortality rates despite recent advances in breast cancer management. Currently, breast cancer is the most common cancer and one of the major health burdens for both developing and developed countries. Purpose to evaluate the impact of neoadjuvant chemotherapy in female patients stage 1, 2a breast cancer with breast cup (A-C) Patients and Methods we collected data from the records of female patients with breast cancer of stage 1,2a who had undergone documented preoperative biopsy and underwent chemotherapy neoadjuvant therapy at Ain Shams University Hospitals from September 2017 to June 2018. An informed consent was taken from all the patients sharing in the study. Results this study favors the idea of Neoadjuvant chemotherapy usage prior to any surgical intervention in early stage breast cancer. However, there were other studies that questions its role and demand a reconsideration about the oncological and clinical outcome which require further investigation. Conclusion it is clinically important to evaluate the value of the neoadjuvant chemotherapy in early stage breast cancer as it directs the future therapy. Although there is no obvious opinion with or against the neoadjuvant chemotherapy but through our studies the result support its significant role in downsizing and downgrading the tumor.